A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis/Metabolic Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis
Year: 2024
Type: Pharmaceutical - Other
Phase: III
Indication: Nonalcoholic Fatty Liver Disease
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Year: 2024
Type: Pharmaceutical - Other
Phase: III
Indication: Nonalcoholic Fatty Liver Disease
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Nonalcoholic Fatty Liver Disease (NAFLD)
Year: 2024
Type: Pharmaceutical - Other
Phase: III
Indication: Nonalcoholic Fatty Liver Disease
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine when Coadministered with Seasonal Inactivated Influenza Vaccine in Adults ≥65 Years of Age.
Year: 2022
Type: Vaccine
Phase: III
Indication: Healthy
A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly.
Year: 2019
Type: Vaccine
Phase: III
Indication: Healthy
A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for12 weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
Year: 2006
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A Phase 3, Randomized, Double blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy.
Year: 2020
Type: Musculoskeletal
Phase: III
Indication: Psoriatic Arthritis
A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMARD Therapy.
Year: 2020
Type: Musculoskeletal
Phase: III
Indication: Psoriatic Arthritis
A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
Year: 2007
Type: Pharmaceutical - Pain
Phase: III
Indication: Pain - General
A Randomised Double-Blind, Placebo-and-Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended –Release (ER) in Subjects with Moderate to Severe Chronic Low Back Pain.